|
Item 7.01.
|
Regulation FD Disclosure.
|
On October 28, 2019, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing updated data for two of
its programs, namely (1) its Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or
metastatic solid tumors and (2) preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. The data were presented on
October 28, 2019 in poster sessions at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, MA (the “Triple Meeting”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the
presentations are furnished as Exhibit 99.3 and Exhibit 99.4 to this Current Report on Form 8-K.
On October 29, 2019, the Company issued a press release announcing updated data for two of its programs, namely (1) updated results
of its phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036) and (2) its Phase 1 study
of DCC-3014, an oral inhibitor of CSF1R, to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors, including diffuse-type tenosynovial giant cell tumor.
The data were presented on October 29, 2019 in poster sessions at the Triple Meeting. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K, and a copy of the
presentations are furnished as Exhibit 99.5 and Exhibit 99.6 to this Current Report on Form 8-K.
The furnishing of the attached press releases and presentations is not an admission as to the materiality of any information therein. The
information contained in the press releases and the presentations is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange
Commission, or the SEC, and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report,
although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important
information about forward looking statements, see the “Cautionary Note Regarding Forward-Looking Statements” section of the press releases in Exhibit 99.1 and Exhibit 99.2 attached hereto.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1,
Exhibit 99.2, Exhibit 99.3, Exhibit 99.4, Exhibit 99.5 and Exhibit 99.6 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities
of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press releases attached as Exhibit 99.1 and Exhibit 99.2 to this Current Report and in the
presentations attached as Exhibit 99.3, Exhibit 99.4, Exhibit 99.5, Exhibit 99.6 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.